Reply to ‘Personalized treatment of immune-related adverse events — balance is required’
نویسندگان
چکیده
منابع مشابه
Clinical assessment of immune-related adverse events
Immunotherapy through checkpoint inhibitors is now standard practice for a growing number of cancer types, supported by overall improvement of clinical outcomes and better tolerance. One anti-CTLA-4 antibody (ipilimumab), two anti-PD-1 antibodies (pembrolizumab and nivolumab) and three anti-PD-L1 antibodies (atezolizumab, avelumab and durvalumab) have been approved for clear benefits across div...
متن کاملManaging immune-related adverse events to ipilimumab: a nurse's guide.
Ipilimumab is a U.S. Food and Drug Administration-approved novel T-cell potentiator that improves survival in metastatic melanoma. Ipilimumab blocks cytotoxic T-lymphocyte antigen-4, a negative regulator of the immune response, thus promoting T-cell activation and prolonging a patient's antitumor response. However, that action may produce a mechanism-related spectrum of immune-related adverse e...
متن کاملImmune-related adverse events during anticancer immunotherapy: Pathogenesis and management
Immunotherapy is one of the most recent systemic treatments to emerge for use in oncology, and is based on the blocking of inhibitory immune checkpoints to potentiate the immune response to cancer. The anti-cytotoxic T lymphocyte-associated antigen-4 antibody ipilimumab and anti-programmed cell death protein 1 antibodies, including nivolumab and pembrolizumab, are currently available and widely...
متن کاملReply to Retrospective evaluation of cetuximab-related adverse events from claims databases—methodological concerns
Maier et al. [1] questioned the algorithm we applied to identify infusion reactions (IRs) associated with cetuximab using claims data and the appropriateness of comparing rates of IRs from a claims data analysis with those of clinical trials. Because there is no International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code for IRs, we identified IRs based on IR-...
متن کاملPharmacogenetics to predict drug-related adverse events.
Identification of reliable markers to predict drug-related adverse events (DRAEs) is an important goal of the pharmaceutical industry and others within the healthcare community. We have used genetic polymorphisms, including the most frequent source of variation (single nucleotide polymorphisms, SNPs) in the human genome, in pharmacogenetic approaches designed to predict DRAEs. Three studies exe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Clinical Oncology
سال: 2020
ISSN: 1759-4774,1759-4782
DOI: 10.1038/s41571-020-0401-3